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Checklist of Items for Reporting Trials of Nonpharmacologic Treatments* 
Section Item Standard CONSORT Description Extension for Nonpharmacologic Trials 
Reported in 
section, paragraph 
number 
Title and abstract† 1 
 
How participants were allocated to 
interventions (e.g., “random allocation,” 
“randomized,” or “randomly assigned”) 
In the abstract, description of the experimental 
treatment, comparator, care providers, centers, 
and blinding status 
Abstract, 
paragraphs 1-
5 
Introduction     
Background 2 Scientific background and explanation of 
rationale 
 Background, 
paragraphs 5-
8 
Methods     
Participants† 3 Eligibility criteria for participants and the 
settings and locations where the data were 
collected 
When applicable, eligibility criteria for centers 
and those performing the interventions 
Participants, 
paragraph 1  
Interventions† 4 Precise details of the interventions intended 
for each group and how and when they were 
actually administered 
Precise details of both the experimental 
treatment and comparator  
Intervention, 
paragraphs 1-
2(iCST), 
Treatment as 
usual (TAU), 
paragraph 1 
 4A  Description of the different components of the 
interventions and, when applicable, descriptions 
of the procedure for tailoring the interventions to 
individual participants 
Intervention, 
paragraphs 1-
2(iCST), 
Treatment as 
usual (TAU), 
paragraph 1 
 4B  Details of how the interventions were 
standardized 
Intervention, 
paragraphs 1-
2(iCST), 
Treatment as 
usual (TAU), 
paragraph 1 
 4C  Details of how adherence of care providers with 
the protocol was assessed or enhanced 
Treatment 
adherence, 
caregiver 
training, and 
support, 
paragraph 1 
Objectives 5 Specific objectives and hypotheses  Introduction, 
paragraphs 6-
8 
Outcomes 6 Clearly defined primary and secondary 
outcome measures and, when applicable, any 
methods used to enhance the quality of 
measurements (e.g., multiple observations, 
training of assessors) 
 Outcome 
measures for 
the person 
with 
dementia, 
paragraphs 1 
& 2, outcome 
measures for 
the caregiver, 
paragraph 1 
Sample size† 7 How sample size was determined and, when 
applicable, explanation of any interim analyses 
and stopping rules 
When applicable, details of whether and how the 
clustering by care providers or centers was 
addressed 
Sample size, 
paragraph 1 
Randomization– 
sequence generation† 
8 Method used to generate the random allocation 
sequence, including details of any restriction 
(e.g., blocking, stratification) 
When applicable, how care providers were 
allocated to each trial group 
Randomization 
and blinding, 
paragraph 1 
Allocation concealment 9 Method used to implement the random 
allocation sequence (e.g., numbered containers 
or central telephone), clarifying whether the 
sequence was concealed until interventions 
were assigned 
 Randomization 
and blinding, 
paragraph 1 
Implementation 10 Who generated the allocation sequence, who 
enrolled participants, and who assigned 
participants to their groups 
 Randomization 
and blinding, 
paragraph 1 
Blinding (masking)† 11A 
 
Whether or not participants, those 
administering the interventions, and those 
assessing the outcomes were blinded to group 
assignment 
Whether or not those administering co-
interventions were blinded to group assignment 
Randomization 
and blinding, 
paragraph 1 
 11B  If blinded, method of blinding and description of 
the similarity of interventions† 
Randomization 
and blinding, 
paragraph 1 
Statistical methods† 12 Statistical methods used to compare groups for 
primary outcome(s); methods for additional 
analyses, such as subgroup analyses and 
adjusted analyses 
When applicable, details of whether and how the 
clustering by care providers or centers was 
addressed 
Statistical 
Analysis, 
paragraph 1, 
Adherence 
analyses, 
paragraph 1, 
Exploratory 
analyses, 
paragraph 1 
Results     
Participant flow† 13 Flow of participants through each stage (a 
diagram is strongly recommended)---
specifically, for each group, report the 
numbers of participants randomly assigned, 
receiving intended treatment, completing the 
study protocol, and analyzed for the primary 
outcome; describe deviations from study as 
planned, together with reasons 
The number of care providers or centers 
performing the intervention in each group and 
the number of patients treated by each care 
provider or in each center 
Trial design 
and setting, 
paragraph 1 
Implementation of 
intervention† 
New 
item 
 Details of the experimental treatment and 
comparator as they were implemented 
Intervention, 
paragraphs 1 
& 2, 
Treatment as 
usual (TAU), 
paragraph 1 
Recruitment 14 Dates defining the periods of recruitment and 
follow-up 
 Preliminary 
analyses, 
paragraph 1  
Baseline data† 15 Baseline demographic and clinical 
characteristics of each group 
 
When applicable, a description of care providers 
(case volume, qualification, expertise, etc.) and 
centers (volume) in each group 
Preliminary 
analyses, 
paragraph 1, 
Table 1 
Numbers analyzed 16 Number of participants (denominator) in each 
group included in each analysis and whether 
analysis was by “intention-to-treat”; state the 
results in absolute numbers when feasible 
(e.g., 10/20, not 50%) 
 Preliminary 
analyses, 
paragraph 1 
Outcomes and 
estimation 
17 For each primary and secondary outcome, a 
summary of results for each group and the 
estimated effect size and its precision (e.g., 
95% confidence interval)  
 Outcomes for 
person with 
dementia, 
paragraph 1, 
Caregiver 
outcomes, 
paragraph 1 
Ancillary analyses 18 Address multiplicity by reporting any other 
analyses performed, including subgroup 
analyses and adjusted analyses, indicating 
those prespecified and those exploratory 
 Adherence 
analysis, 
paragraphs 1-
4, Exploratory 
analyses, 
Outcomes for 
people with 
dementia, 
paragraph 1, 
Outcomes for 
caregivers, 
paragraph 1 
Adverse events 19 All important adverse events or side effects in 
each intervention group 
 Serious 
Adverse 
Events (SAEs), 
paragraph 1  
Discussion    Discussion, 
paragraphs 1-
14 
Interpretation† 20 Interpretation of the results, taking into 
account study hypotheses, sources of potential 
bias or imprecision, and the dangers associated 
with multiplicity of analyses and outcomes 
In addition, take into account the choice of the 
comparator, lack of or partial blinding, and 
unequal expertise of care providers or centers in 
each group 
24-31 
Generalizability† 21 Generalizability (external validity) of the trial 
findings 
Generalizability (external validity) of the trial 
findings according to the intervention, 
comparators, patients, and care providers and 
centers involved in the trial 
Discussion, 
paragraph 7 
Overall evidence 22 General interpretation of the results in the 
context of current evidence 
 Discussion, 
paragraphs 1-
14 
*Additions or modifications to the CONSORT checklist. CONSORT = Consolidated Standards of Reporting Trials. 
†This item was modified in the 2007 revised version of the CONSORT checklist. 
